TenX Keane shareholders approve business combination with Citius Oncology; redemptions total $49.3M

CITIUS ONCOLOGY, INC.

All eight proposals approved, including business combination, domestication to Delaware, name change to Citius Oncology, and 15M-share stock incentive plan.
4,297,828 shares redeemed at ~$11.46 per share, aggregating $49,265,965 from trust account.
Eight directors elected to staggered terms: Myron Holubiak, Joel Mayersohn, Dr. Eugene Holuka, Robert Smith, Carol Webb, Suren Dutia, Leonard Mazur, Dennis McGrath.
Business combination involves Citius Oncology (spin-off from Citius Pharma) merging into TenX; closing conditions still pending.
Incentive plan authorizes options, SARs, restricted stock, RSUs, and cash awards for employees, directors, and consultants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.